Replies to post #28560 on Biotech Values

[io_io]

re: THLD & DNDN

Never even heard of THLD, but I see it must have had a $500m cap before today.

But the point of my post is that it puts DNDN in a good light.

[poorgradstudent]

>Anyone nibbling on THLD at this level?<

I wouldn't touch it now. I was looking at it a few months ago, and they really have very little other than this bph drug (i went short briefly because i thought it was overvalued).

I think the bph indication is large enough and ultimately benign enough that this noted toxicity could be a show stopper. If not in the clinic, then at least the marketplace.